OBJECTIVES: V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) specifically designed for adults. It includes 8 unique serotypes (15A, 15C [from deOAc-15B], 16F, 23A, 23B, 24F, 31 and 35B) not covered by any currently licensed pneumococcal vaccine. According to the National Institute for Public Health and the Environment (RIVM) surveillance data of 2019, the serotypes covered by V116 are responsible for approximately 91% of invasive pneumococcal disease (IPD) in individuals aged 60+, and the unique 8 serotypes were responsible for approximately 11%. This study estimates the potential health and economic impact of vaccination with V116 vs. PCV20 on IPD in adults aged 60+ in the Netherlands.

METHODS: A Markov model was built to estimate the lifetime IPD cases, IPD related deaths, and the associated direct and indirect medical costs among the adults aged 60-79 and 80+ vaccinating with V116 or PCV20. The same serotype specific vaccine effectiveness, and the same vaccine coverage rates (70%) were assumed for the two vaccines.

RESULTS: In adults aged 60-79, compared to no vaccination, V116 prevented 7,525 IPD cases and 1,213 IPD deaths – 20% more than the 6,264 IPD cases and 1,010 IPD deaths prevented by PCV20. The averted IPD cases by V116 saved €103 million in total medical costs – 20% higher than the €86 million costs averted by PCV20.

In adults aged 80+, compared to no vaccination, V116 prevented 1,659 IPD cases and 406 IPD deaths – 20% more than the 1,381 IPD cases and 335 IPD deaths prevented by PCV20. The averted IPD cases by V116 resulted in €23 million reduction in total medical costs – 20% higher than the €19 million costs averted by PCV20.

CONCLUSIONS: In both age groups, comparing with PCV20, V116 led to a greater reduction of both the health and economic burden associated with IPD in the Netherlands.